Working Life Interview: Kim Stratton, CEO, Orphazyme
May 4, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Interview, Orphazyme, Working Life
“Every professional faces challenges. As a woman in industry, particularly in leadership, it adds another dimension to those challenges in …
Lonza and Moderna enter agreement to mass produce coronavirus vaccine
May 4, 2020Sales and Marketing COVID-19, coronavirus
Lonza Group AG and Moderna Inc have entered a deal to develop 1 billion doses of coronavirus vaccines a year. …
FDA approves emergency use of Gilead’s remdesivir for hospitalised COVID-19 patients
May 4, 2020Sales and Marketing COVID-19, FDA, Gilead, coronavirus, remdesivir
Gilead’s antiviral therapy remdesivir has shown tentatively promising efficacy in the race to find an effective treatment for COVID-19, one …
Trump vows to reduce America’s reliance on foreign drug imports
May 4, 2020Sales and Marketing COVID-19, coronavirus
President Donald Trump has vowed to cut the US’s reliance on foreign drugs, singling out China and Ireland as countries …
UK testing experimental treatment for use in COVID-19 patients
May 4, 2020Sales and Marketing COVID-19, coronavirus, coronavirus treatment
British scientists are testing an experimental drug to help some of society’s most vulnerable fight off the COVID-19 coronavirus.
Mike Pompeo says there is evidence COVID-19 was made in a lab, despite US intelligence saying it occurred naturally
May 4, 2020Sales and Marketing COVID-19, Wuhan Institute of virology, coronavirus, lab, pandemic
US Secretary of State Mike Pompeo claimed that there is evidence the COVID-19 coronavirus was created in a lab, despite …
NHS sets out plans to deal with the second phase of the pandemic
May 1, 2020Medical Communications COVID-19, coronavirus
The NHS has set out plans to step up its non-COVID-19 services over the next six weeks. A letter from …
Positive CHMP opinion for BMS and Acceleron’s Reblozyl in transfusion-dependent anaemia sub-populations
May 1, 2020Medical Communications, Sales and Marketing Acceleron, Bristol-Myers Squibb, EU, Reblozyl
Bristol Myers Squibb and Acceleron Pharma’s Reblozyl (luspatercept) has secured a positivr opinion from the European Medicines Agency’s Committee for Medicinal …
COVID-19 pandemic likely to last two years, study says
May 1, 2020Medical Communications COVID-19, coronavirus, pandemic
The coronavirus pandemic is likely to last as long as two years and will not be properly controlled until two-thirds …
Vertex’s Kalydeco seizes EU CHMP recommendation for Kalydeco in R117H+ cystic fibrosis
May 1, 2020Medical Communications, Sales and Marketing Europe, Kalydeco, Vertex, cystic fibrosis
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given its recommendation for the approval …
Top Ten most popular articles on Pharmafile.com this week
May 1, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Gilead, UK, coronaviurs
The search for a COVID-19 treatment has ramped up this week, with two new studies detailing the efficacy of Gilead’s …
Teva’s cancer drug Bendeka protected from generics until 2031, judge rules
April 30, 2020Business Services Bendeka, Teva, Teva and Eagle
A US federal judge has ruled that generic versions of the cancer treatment Bendeka infringe on four separate patents, and …
AstraZeneca joins forces with University of Oxford to develop and manufacture potential coronavirus vaccine
April 30, 2020Manufacturing and Production, Research and Development AstraZeneca, COVID-19, University of Oxford, coronavirus, pharma
A “landmark” partnership has been struck between AstraZeneca and the University of Oxford in the ongoing battle against COVID-19, with …
More than half of US states will relax lockdowns by the end of the week
April 30, 2020Business Services COVID-19, Lockdown, coronavirus, quaratine
Nearly half of US states will have their ‘stay-at-home’ orders expire this week, paving the way for much of the …
Two studies reveal “positive” data for Gilead’s remdesivir in hospitalised COVID-19 patients
April 30, 2020Research and Development COVID-19, Gilead, coronavirus, remdesivir
The first findings of two new studies have been revealed detailing the efficacy of Gilead’s antiviral therapy remdesivir in the …
Men most likely to exhibit the worst COVID-19 symptoms, according to a new study
April 30, 2020Business Services COVID-19, coronavirus
Research into coronavirus cases in Shenzhen, China found that men were 2.5 times as likely to exhibit severe symptoms. The …
Arizona GOP lawmakers and AAPS say hydroxychloroquine has 90% chance of helping COVID-19 patients, but data is not based on clinical trials
April 29, 2020Research and Development chloroquine, hydroxychloroquine
The Association of American Physicians and Surgeons (AAPS) wrote a letter to Republican Arizona Governor Doug Ducey urging the wider …
Phase 3 Libtayo monotherapy trial halted early due to strong benefit in advanced non-small cell lung cancer
April 29, 2020Research and Development Cancer, Libtayo, Regeneron, Sanofi, lung cancer
A Phase 3 study of Sanofi and Regeneron’s Libtayo (cemiplimab) as a monotherapy for advanced or metastatic non-small cell lung …
Australia calls for investigation into China’s coronavirus response
April 29, 2020Research and Development Australia, COVID-19, China, coronavirus
Scott Morrison, the Australian Prime Minister, has called for an investigation into the origins of the COVID-19 coronavirus, as Australia …
Pharmafile.com’s weekly COVID-19 news round-up
April 29, 2020Research and Development BARDA, COVID-19, coronavirus, hydroxychloroquine
Hydroxychloroquine continues to feature in coronavirus news. Rick Bright, the Director of BARDA, alleges he was pushed out of his …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
